Get the Stockscreener App
2.62
5.22%
0.13
Entero Therapeutics Inc stock is traded at $2.62, with a volume of 91,540.
It is up +5.22% in the last 24 hours and down -35.47% over the past month.
Entero Therapeutics Inc is a late clinical-stage biopharmaceutical company focused on the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases. The company's programs address unmet needs in GI health and include: latiglutenase, a Phase 3-ready, potentially first-in-class, targeted, oral biotherapeutic for celiac disease; capeserod, a selective 5-HT4 receptor partial agonist for indications including gastroparesis; and adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients in cystic fibrosis and chronic pancreatitis patients with exocrine pancreatic insufficiency.
See More
Previous Close:
$2.49
Open:
$2.45
24h Volume:
91,540
Relative Volume:
0.45
Market Cap:
$8.81M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
-30.50%
1M Performance:
-35.47%
6M Performance:
+121.10%
1Y Performance:
+110.44%
1-Day Range:
$2.40
$2.89
1-Week Range:
$2.40
$3.89
52-Week Range:
$0.9693
$5.84
Entero Therapeutics Inc Stock (ENTO) Company Profile
Name
Entero Therapeutics Inc
Sector
Industry
Phone
561-589-7020
Address
777 YAMATO ROAD, BOCA RATON
Compare ENTO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ENTO
Entero Therapeutics Inc
|
2.62 | 5.29M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Entero Therapeutics Inc Stock (ENTO) Latest News
Entero Therapeutics Delays Q3 10-Q Filing - MSN
ENTO Subsidiary Grid AI Announces Letter of Intent with First Hyperscaler AI Data-Center Customer - Livingston Daily
Will Entero Therapeutics Inc. stock benefit from upcoming earnings reportsWeekly Market Outlook & Weekly High Return Stock Forecasts - newser.com
Entero Regains Nasdaq Compliance With Grid AI Acquisition - Times Herald
12 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
NASDAQ: ENTO’s Grid AI Strikes Texas Hyperscale Deal as its $50M Industrial Software Platform Enters the AI Race - TipRanks
Will Entero Therapeutics Inc. stock rally after Fed decisions2025 Major Catalysts & Safe Capital Growth Plans - newser.com
Will Entero Therapeutics Inc. bounce back from current supportPortfolio Growth Summary & Low Risk Growth Stock Ideas - newser.com
Institutional scanner results for Entero Therapeutics Inc.Weekly Market Outlook & Weekly Market Pulse Updates - newser.com
Entero’s Grid AI Announces Major U.S. Expansion and Incoming Leadership to Accelerate AI Infrastructure Strategy - Markets Financial Content
Entero Therapeutics, Inc. SEC 10-Q Report - TradingView
Published on: 2025-11-19 15:36:56 - newser.com
Grid AI secures deal with stealth hyperscaler for Texas data center - Investing.com Nigeria
Entero's Grid AI Announces Major U.S. Expansion and Incoming Leadership to Accelerate AI Infrastructure Strategy - Digital Journal
Why Entero Therapeutics Inc. stock remains a top recommendationPortfolio Profit Report & Trade Opportunity Analysis - newser.com
Entero Therapeutics (ENTO) Partners on Advanced AI Campus Project - GuruFocus
Grid AI secures deal with stealth hyperscaler for Texas data center By Investing.com - Investing.com South Africa
Entero (NASDAQ: ENTO) Grid AI LOI with First Hyperscaler AI Data-Center Client - Stock Titan
How Entero Therapeutics Inc. stock performs in high volatility marketsShort Setup & Safe Entry Momentum Stock Tips - newser.com
What technical models suggest about Entero Therapeutics Inc.’s comebackJuly 2025 PostEarnings & Weekly Hot Stock Watchlists - newser.com
Entero's Grid AI Prepares for Major U.S. Expansion with New Leadership Appointments to Accelerate AI Infrastructure Strategy - Pensacola News Journal
Entero Subsidiary Grid AI Accelerates Expansion into Hyperscaler AI Data Center Market with Integration of LV Grid - St. Cloud Times
What Risks Could Derail Mena Mani Industries Limiteds Growth Story in YEARCovered Call Writing & Free Trading Signals to Sharpen Your Edge - earlytimes.in
Why analysts remain bullish on Entero Therapeutics Inc. stockJuly 2025 Earnings & Capital Efficiency Focused Ideas - newser.com
Entero Therapeutics Inc Stock (ENTO) Financials Data
There is no financial data for Entero Therapeutics Inc (ENTO). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):